Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH001 Pharmacokinetics and Safety in Healthy Volunteers
NCT05163691Phase 1Completed
- Sponsor
- GH Research PLC
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mebufotenin in treatment-resistant depression (TRD) (5 arms), sponsored by GH Research PLC. Primary endpoint: Pharmacokinetic parameters of 5-MeO-DMT and bufotenine at 4 hours. Started Jun 2021; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05163691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163691.